Surgical management of 144 diffuse‐type TGCT patients in a single institution: A 20‐year cohort study

Geert Spierenburg(Leiden University Medical Center), Michiel A. J. van de Sande(Leiden University Medical Center), Hans Gelderblom(Leiden University Medical Center), Kirsten van Langevelde(Leiden University Medical Center), L. van der Heijden(Leiden University Medical Center), Robert J. P. van der Wal(Leiden University Medical Center), M.J.L. Mastboom(Leiden University Medical Center)
Journal of Surgical Oncology
June 23, 2022
10.1002/jso.26991
Cited by 15

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k